Takeda Pharmaceutical Company Limited

Toyo Kohan Co., Ltd.

Toyo Seikan Group Holdings, Ltd.

Satoshi Mikami

Shinji Morimoto

Takeshi Yamamoto

Satoshi Yamamoto

Shinji Nakamura

Masaki Daini

Norihito Tokunaga

Kazuaki Takami

Minoru Nakamura

Tatsuki Koike

Masaki Seto

Takahiko Taniguchi

Yuichi Kajita

Yuhei Miyanohana

Masataka Murakami

Tomoaki Hasui

Masaki Ogino

Kohei Takeuchi

Kouichi Iwanaga

Tohru Yamashita

Izumi Nomura

Tomoko Ashizawa

Makoto Kamata

Yuya Oguro

Shigemitsu Matsumoto

Shigekazu Sasaki

Taku Kamei

Mitsuhiro Ito

Jumpei Aida

Koichiro Fukuda

Takeshi Wakabayashi

Yuta Tanaka

Yasufumi Wada

Taisuke Tawaraishi

Masanori Kawasaki

Sachie Takashima

Hiroyuki Kakei

Yasushi Hattori

Hideo Suzuki

Tsuneo Oda

Xin Liu

Takahiro Sugimoto

Yasutaka Hoashi

Masami Yamada

Hidekazu Tokuhara

Toshihiro Imaeda

Yoshiteru Ito

Keisuke Imamura

Shoji Fukumoto

Keiko Kakegawa

Minoru Sasaki

Yasutomi Asano

Atsuko Ochida

Takahiro Matsumoto

Tohru Miyazaki

Masakuni Kori

Zenichi Ikeda

Tatsuhiko Fujimoto

Osamu Ujikawa

Kenichiro Shimokawa

Fumiaki Kikuchi

Wataru Kurokawa

Kunihiro Yoshimura

Kentaro Rikimaru

Mitsuhide Aihara

Hiromichi Sugimoto

Tomohiro Ohashi

Munemitsu Hirotsu

Takahito Kasahara

Nao Morishita

Naomi Taguchi

Shogo Hashizume

Satoko Fukutomi

Kawasaki Masanori

Florian Pünner

Norio Oyabu

Fumie Yamaguchi

Chunxiang Wang

Toru Yamashita

The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compounds

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Heterocyclic compound and use thereof

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound and application thereof

The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Substituted pyrrolidine compound and use thereof

Provided is a surface-treated steel sheet with a compound layer containing F and composed essentially or Zr at least on one surface thereof, wherein the Zr amount is 80 to 350 mg/mand the F amount is 0.5 to 10 mg/mwithin the layer, and an organic resin coated metal container manufactured using the surface-treated steel sheet. The surface-treated steel sheet of the present invention is manufactured through forming a layer having the Zr amount of 80 to 350 mg/mat least on one surface of a steel sheet by cathode electrolytic treatment in an aqueous solution containing a Zr ion and F ion, and subsequently adjusting the surface to control the F amount to 0.5 to 10 mg/mby one or more treatments selected from immersion and spraying with an ion-containing aqueous solution and cathode electrolytic treatment in the ion-containing aqueous solution.

Surface-treated steel sheet, organic resin coated metal container, and method for producing surface-treated steel sheet

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Nitrogenated heterocyclic compound

Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors

Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification,or a salt thereof.

Sulfonamide derivative and use thereof

Growing community of inventors

Kanagawa, Japan

Satoshi Mikami